Form 4: Integrated Biopharma Director Reports Stock Transfers

Director William H. Milmoe reported the transfer of over 11 million shares of Integrated Biopharma common stock.

Summary

• Director William H. Milmoe filed a Form 4 reporting the transfer of 8,966,547 shares from CD Financial, LLC to CDDS 2.0, LLC.
• An additional 2,235,417 shares were transferred from the Carl DeSantis Revocable Trust to CDDS 2.0, LLC.
• The transactions were executed as gifts on April 15, 2026.
• Following these transactions, the reporting person maintains direct ownership of 138,667 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting a change in beneficial ownership rather than a change in the company's fundamental business health.

Positives

• The filing provides transparency regarding significant changes in beneficial ownership structure.

Negatives

• The transfer of large blocks of shares to a third-party entity (CDDS 2.0, LLC) may signal a consolidation of voting power or a shift in control dynamics.

Risks

• Concentration of ownership in CDDS 2.0, LLC could impact future corporate governance and decision-making processes.

Future Outlook

No specific forward-looking guidance or operational outlook was provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that insider ownership changes of this magnitude often precede strategic restructuring or changes in control, which are common in the small-cap biopharma sector.

Comparison to Industry Standards

• The filing is a standard regulatory disclosure for insider transactions and does not deviate from typical SEC reporting requirements for publicly traded companies.

Related Party Transactions

• The transfers involve entities controlled by Damon DeSantis and the Carl DeSantis Revocable Trust, indicating significant related-party activity.

Stakeholder Impact

• Shareholders should be aware of the consolidation of shares into CDDS 2.0, LLC, which may influence future voting outcomes.

Next Steps

• Monitor future filings for potential changes in board composition or control of CDDS 2.0, LLC.

Key Dates

Keywords

INBP, Integrated Biopharma, Form 4, Insider Trading, Beneficial Ownership, Stock Transfer